Metronidazole vaginal gel - Allergan

Drug Profile

Metronidazole vaginal gel - Allergan

Alternative Names: GW 05; Nuvessa; Product 55394

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator Graceway Pharmaceuticals
  • Developer Allergan
  • Class Antibacterials; Antiprotozoals; Nitroimidazoles; Radiosensitisers; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bacterial vaginosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 24 Mar 2014 Registered for Bacterial vaginosis in USA (Vaginal, 1.3%) - First global approval
  • 01 May 2013 Metronidazole vaginal gel licensed to Actavis worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top